Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Inflammation and immune characteristics of the tumour microenvironment have therapeutic significance. The aim of this study was to investigate the clinical impact on disease progression in human extrahepatic cholangiocarcinoma (ECC). A total of 114 consecutive ECC patients with curative resection between 2000 and 2014 were enrolled. Tumour infiltrating CD66b + neutrophils (TANs; tumour associated neutrophils), CD163 + M2 macrophages (TAMs; tumour associated macrophages), CD8 + T cells, and FOXP3 + regulatory T cells (Tregs) were assayed by immunohistochemistry, and their relationships with patient clinicopathological characteristics and prognosis were evaluated. Tumour associated neutrophils were inversely correlated with CD8 + T cells ( P =0.0001) and positively correlated with Tregs ( P =0.001). High TANs ( P =0.01), low CD8 + T cells ( P =0.02), and high Tregs ( P =0.04) were significantly associated with poor overall survival (OS). A high-risk signature, derived from integration of intratumoural inflammatory and immune cells, was significantly associated with poor recurrence-free survival ( P =0.01) and OS ( P =0.0008). A high-risk signature was correlated with postoperative distant metastases. Furthermore, a high-risk signature was related to the resistance to gemcitabine-based chemotherapy used after recurrence. Our data showed that tumour infiltrating inflammatory and immune cells may play a pivotal role in ECC progression and a high-risk signature predicted poor prognosis in ECC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 14×
“High TANs (P¼ 0.01), low CD8þ T cells (P¼ 0.02), and high Tregs (P¼ 0.04) were significantly associated with poor overall survival (OS).”
BackgroundInfluentialMicroenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684 · cited 1×
“In the past two decades, the tumour microenvironment has also emerged as an equally important determinant of tumour behaviour (Joyce and Pollard, 2009; McAllister and Weinberg, 2014).”
BackgroundIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 2×
“In clinical practice, a small number of CD8þ T cells (Naito et al, 1998; Zhang et al, 2003) and a large number of Tregs (Curiel et al, 2004; Hiraoka et al, 2006; Tanaka and Sakaguchi (2017)) have also been associated with tumour development.”
BackgroundInflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860 · cited 2×
“Regulatory T cells (Tregs) have also been shown to support tumour growth and invasion by suppressing host immune responses (Plitas and Rudensky, 2016; Tanaka and Sakaguchi, 2017).”
BackgroundNeutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830 · cited 17×
“High TANs (P¼ 0.01), low CD8þ T cells (P¼ 0.02), and high Tregs (P¼ 0.04) were significantly associated with poor overall survival (OS).”
BackgroundInfluentialIL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703 · cited 14×
“High TANs (P¼ 0.01), low CD8þ T cells (P¼ 0.02), and high Tregs (P¼ 0.04) were significantly associated with poor overall survival (OS).”
BackgroundInfluentialGene expression in fixed tissues and outcome in hepatocellular carcinoma
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804525 · Cited by 1,286
Cited by
Targeting tumor-associated macrophages to synergize tumor immunotherapy
Xiang, X., Wang, J., Lu, D., & Xu, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00484-9 · Cited by 966
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
Kumari, N., & Choi, S. H. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02272-x · Cited by 315
Immunology and immunotherapy of cholangiocarcinoma
Greten, T. F., Schwabe, R., Bardeesy, N., Ma, L., Goyal, L., Kelley, R. K., & Wang, X. W. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00741-4 · Cited by 193
The tumour microenvironment and immune milieu of cholangiocarcinoma
Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International · doi:10.1111/liv.14098 · Cited by 187
Surendran, V., Rutledge, D., Colmon, R., & Chandrasekaran, A. (2021) · Biofabrication · doi:10.1088/1758-5090/abe1cf · Cited by 99
Research progress of T cells in cholangiocarcinoma
Wang, Z., Dai, Y., Zhou, Y., Wang, Y., Chen, P., Li, Y., Zhang, Y., Wang, X., Hu, Y., Li, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1453344 · Cited by 2
Metadata
- Authors
- Kitano, Y., Okabe, H., Yamashita, Y.-I., Nakagawa, S., Saito, Y., Umezaki, N., Tsukamoto, M., Yamao, T., Yamamura, K., Arima, K., Kaida, T., Miyata, T., Mima, K., Imai, K., Hashimoto, D., Komohara, Y., Chikamoto, A., Ishiko, T., & Baba, H.
- Venue
- British Journal of Cancer
- Published
- 2017-11-09
- Volume
- 118
- Issue
- 2
- Pages
- 171-180
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2767473306
- Cited by
- 144
- References
- 12
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.